Is This AI Drug Discovery Stock a Bargain?

AbCellera’s recent 23% share price decline highlights significant concerns regarding the viability of its AI-powered drug discovery engine. While the company maintains $780 million in cash, its business model faces scrutiny due to a 41% failure rate on completed programs and a lack of meaningful late-stage pipeline progress. The company’s strategic shift toward in-house drug development and resource-intensive partnerships deviates from the original "engine" model that promised high-volume, low-cost royalty generation. This transition, coupled with heavy capital expenditure on new facilities and internal programs, creates substantial financial pressure. Without clear evidence that the platform effectively reduces development time or increases success rates, the company’s long-term value remains uncertain, especially as its depressed stock price complicates potential capital-raising efforts.